Resources · Microbiology & Medications
The microbes and the medicines.
The microbiology behind chest infections, and a physiotherapist-focused guide to the main medicines used in heart and lung disease.
Cardiorespiratory Physiotherapy
Microbiology & Medications · area 04 of 07
Outcome Measures & Clinical Skills
Bugs & infection
Microbiology & Infection
The microbes behind chest infections and why they matter.
FoundationMicrobiology & InfectionThe bugs behind chest infections and why they matter.InfectionPseudomonas aeruginosaEradication, chronic infection and cross-infection in bronchiectasis and CF.InfectionBurkholderia cepacia ComplexCepacia syndrome, segregation and transplant eligibility.InfectionMRSA & Staphylococcus aureusWhen to treat, when to eradicate, and what the evidence will not yet say.InfectionNon-Tuberculous Mycobacteria (NTM)M. avium and related slow-growing lung infections.
Medicines & how they work
Medications
A physiotherapist-focused reference to the main medicines in heart and lung disease.
Start hereMedications OverviewDrug classes and how they affect a physiotherapy session.InhaledInhaled MedicationDevice types, drug classes and technique points.InhaledInhalers by IngredientEvery inhaler by what is actually in it — ingredient fingerprint, device code, and the duplicate-ingredient check.InhaledAsthma Treatment LevelsTwo reliever strategies, four levels, and the technique-and-adherence gate before every step up.SystemicSteroids (Corticosteroids)Inhaled preventers and oral steroid courses.AcuteAntibioticsOral and IV antibiotics in respiratory infection.AcuteHow GPs Prescribe in a COPD ExacerbationThe primary care algorithm, and the four points where a physiotherapist changes the outcome.AdjunctNebulised & Mucoactive TherapyMucoactive and airway-clearance adjunct agents.AdjunctOxygen TherapyOxygen as a prescribed drug, delivery devices and humidification.SpecialistBiologics in Respiratory DiseaseTargeted therapy beyond salbutamol and prednisone — patient guide + clinician evidence.ComorbidityGLP-1 and Dual GIP/GLP-1 Receptor AgonistsMechanism, indications, dose escalation, trial evidence and discontinuation data.EmergingThe Cystic Fibrosis Drug PipelineFrom airway clearance and antibiotics to CFTR modulators — and the RNA and gene therapies in trials now.EmergingThe IPF Drug PipelineFrom the harm of immunosuppression to two antifibrotics — and the PDE4B inhibitors now in phase 3.
No resources found
Try a different search term.
These resources are for general education and are not a substitute for individualised assessment by a qualified clinician. If your symptoms change suddenly or severely, seek urgent medical care.